Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 5/20 | 0.39 |
| ▸ | CPA2 | P48052 | 5/20 | 0.39 |
| ▸ | CPA4 | Q9UI42 | 5/20 | 0.39 |
| ▸ | MMP3 | P08254 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416221 | 0.78 | MMP3 (0.57) | CPA1CPA2CPA4MMP3ERAP2 | |
| SCHEMBL8343741 | 0.69 | MMP3 (0.47) | CPA1CPA2CPA4MMP3MMP2 | |
| SCHEMBL7396366 | 0.68 | MMP3 (0.42) | MMP3MMP2 | |
| SCHEMBL7374189 | 0.68 | MMP3 (0.52) | CPA1CPA2CPA4MMP3MMP2 | |
| SCHEMBL7391702 | 0.66 | MMP3 (0.64) | CPA1CPA2CPA4MMP3ERAP2 | |
| SCHEMBL19289874 | 0.64 | ALOX5 (0.63) | SMN1; SMN2 | |
| SCHEMBL8858194 | 0.63 | MMP3 (0.39) | MMP3MMP2MMP1 | |
| SCHEMBL8344554 | 0.62 | HPGD (0.38) | MMP3SMN1; SMN2LMNAPKMREN | |
| SCHEMBL8819128 | 0.61 | MEN1 (0.51) | MMP3LMNAMMP2HPGDMMP1 | |
| SCHEMBL8818911 | 0.61 | MEN1 (0.51) | MMP3LMNAMMP2HPGDMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | CPA1 469/4885CPA2 625/4885CPA4 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.